nach oben

Current HIV/AIDS Reports

Erschienen in:

23.03.2018 | Co-infections and Comorbidity (S Naggie, Section Editor)

Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era

verfasst von: Jennifer J. Chang, Neaka Mohtashemi, Debika Bhattacharya

Erschienen in: Current HIV/AIDS Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to summarize the prevalence and clinical implications of the isolated anti-HBc serologic profile in HIV-infected individuals. We highlight the rare but important issue of HBV reactivation in the setting of HCV therapy and describe an approach to management.

Recent Findings

The isolated anti-HBc pattern, a profile that most often indicates past exposure to HBV with waning anti-HBs immunity, is found commonly in HIV-infected individuals, particularly those with HCV. Some large cohort studies demonstrate an association with advanced liver disease, while others do not. Conversely, meta-analyses have found an association between occult HBV infection (a component of the isolated anti-HBc pattern) and advanced liver disease and hepatocellular carcinoma in HIV-uninfected individuals. In HIV-uninfected individuals with anti-HBc positivity, HBV reactivation has been reported in patients receiving HCV therapy. This phenomenon is likely the result of disinhibition of HBV with HCV eradication.

Summary

In HIV-infected patients, the long-term liver outcomes associated with the isolated anti-HBc pattern remain to be fully elucidated, supporting the need for large cohort studies with longitudinal follow-up. HBV reactivation during HCV DAA therapy has been well-described in HIV-uninfected cohorts and can inform algorithms for the screening and management of the isolated anti-HBc pattern in this population.

Bhattacharya D, Tseng CH, Tate JP, et al. Isolated hepatitis B Core antibody is associated with advanced hepatic fibrosis in HIV/HCV infection but not in HIV infection alone. J Acquir Immune Defic Syndr. 2016;72(1):e14–7. https://doi.org/10.1097/QAI.0000000000000941.CrossRefPubMedPubMedCentral

Blondot ML, Bruss V, Kann M. Intracellular transport and egress of hepatitis B virus. J Hepatol. 2016;64(1 Suppl):S49–59. https://doi.org/10.1016/j.jhep.2016.02.008.CrossRefPubMed

Bowden S, Locarnini S, Chang TT, et al. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol. 2015;21(15):4644–51. https://doi.org/10.3748/wjg.v21.i15.4644.CrossRefPubMedPubMedCentral

Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005;42(3):302–8. https://doi.org/10.1016/j.jhep.2004.12.015.CrossRefPubMed

Witt MD, Lewis RJ, Rieg G, Seaberg EC, Rinaldo CR, Thio CL. Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study. Clin Infect Dis. 2013;56(4):606–12. https://doi.org/10.1093/cid/cis908.CrossRefPubMed

Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;36(3):869–75.CrossRefPubMed

Kim JW, Lee SH, Park YS, et al. Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection. Intervirology. 2011;54(6):316–25. https://doi.org/10.1159/000321450.CrossRefPubMed

Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25(1):142–63. https://doi.org/10.1128/CMR.00018-11.CrossRefPubMedPubMedCentral

Palacios R, Mata R, Hidalgo A, et al. Very low prevalence and no clinical significance of occult hepatitis B in a cohort of HIV-infected patients with isolated anti-HBc seropositivity: the BHOI study. HIV Clin Trials. 2008;9(5):337–40. https://doi.org/10.1310/hct0905-337.CrossRefPubMed

10.

Khamduang W, Ngo-Giang-Huong N, Gaudy-Graffin C, et al. Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women. Clin Infect Dis. 2013;56(12):1704–12. https://doi.org/10.1093/cid/cit166.CrossRefPubMedPubMedCentral

11.

Neau D, Winnock M, Jouvencel AC, et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis. 2005;40(5):750–3. https://doi.org/10.1086/427882.CrossRefPubMed

12.

Firnhaber C, Viana R, Reyneke A, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg. South Africa Int J Infect Dis. 2009;13(4):488–92. https://doi.org/10.1016/j.ijid.2008.08.018.CrossRefPubMed

13.

Saha D, Pal A, Sarkar N, et al. Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India. PLoS One. 2017;12(6):e0179035. https://doi.org/10.1371/journal.pone.0179035.CrossRefPubMedPubMedCentral

14.

Tsui JI, French AL, Seaberg EC, et al. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin Infect Dis. 2007;45(6):736–40. https://doi.org/10.1086/520989.CrossRefPubMedPubMedCentral

15.

Chadwick D, Stanley A, Sarfo S, et al. Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa. AIDS. 2013;27(1):139–41. https://doi.org/10.1097/QAD.0b013e3283589879.CrossRefPubMed

16.

French AL, Hotton A, Young M, et al. Isolated hepatitis B Core antibody status is not associated with accelerated liver disease progression in HIV/hepatitis C coinfection. J Acquir Immune Defic Syndr. 2016;72(3):274–80. https://doi.org/10.1097/QAI.0000000000000969.CrossRefPubMedPubMedCentral

17.

Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36(5):681–6.CrossRefPubMed

18.

Shire NJ, Rouster SD, Stanford SD, et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44(3):309–14. https://doi.org/10.1097/QAI.0b013e31802e29a9.CrossRefPubMed

19.

Karaosmanoglu HK, Aydin OA, Nazlican O. Isolated anti-HBc among HIV-infected patients in Istanbul. Turkey HIV Clin Trials. 2013;14(1):17–20. https://doi.org/10.1310/hct1401-17.CrossRefPubMed

20.

Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative south African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a tertiary hospital. J Med Virol. 2009;81(3):406–12. https://doi.org/10.1002/jmv.21418.CrossRefPubMed

21.

Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20(9):1253–60. https://doi.org/10.1097/01.aids.0000232232.41877.2a.CrossRefPubMed

22.

Lo Re V 3rd, Wertheimer B, Localio AR, et al. Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol. 2008;43(1):32–6. https://doi.org/10.1016/j.jcv.2008.03.030.CrossRefPubMed

23.

Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV cohort study. Eur J Clin Microbiol Infect Dis. 1998;17(1):6–13.CrossRefPubMed

24.

Liang SH, Chen TJ, Lee SS, et al. Risk factors of isolated antibody against core antigen of hepatitis B virus: association with HIV infection and age but not hepatitis C virus infection. J Acquir Immune Defic Syndr. 2010;54(2):122–8. https://doi.org/10.1097/QAI.0b013e3181daafd5.PubMed

25.

French AL, Operskalski E, Peters M, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis. 2007;195(10):1437–42. https://doi.org/10.1086/515578.CrossRefPubMedPubMedCentral

26.

Pogany K, Zaaijer HL, Prins JM, Wit FW, Lange JM, Beld MG. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retrovir. 2005;21(11):922–6. https://doi.org/10.1089/aid.2005.21.922.CrossRefPubMed

27.

Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis. 2013;45(3):238–44. https://doi.org/10.1016/j.dld.2012.09.021.CrossRefPubMed

28.

Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32(2):231–40. https://doi.org/10.1111/j.1478-3231.2011.02481.x.CrossRefPubMed

29.

Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol. 2016;22(39):8720–34. https://doi.org/10.3748/wjg.v22.i39.8720.CrossRefPubMedPubMedCentral

30.

Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol. 2013;59(4):696–700. https://doi.org/10.1016/j.jhep.2013.05.043.CrossRefPubMed

31.

Lok AS, Everhart JE, Di Bisceglie AM, et al. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54(2):434–42. https://doi.org/10.1002/hep.24257.CrossRefPubMedPubMedCentral

32.

Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341(1):22–6. https://doi.org/10.1056/NEJM199907013410104.CrossRefPubMed

33.

Zignego AL, Fontana R, Puliti S, et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol. 1997;51(4):313–8.CrossRefPubMed

34.

Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol. 2001;63(3):220–7.CrossRefPubMed

35.

Fukuda R, Ishimura N, Niigaki M, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol. 1999;58(3):201–7.CrossRefPubMed

36.

De Maria N, Colantoni A, Friedlander L, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000;95(12):3529–36. https://doi.org/10.1111/j.1572-0241.2000.03371.x.CrossRefPubMed

37.

Jongjirawisan Y, Ungulkraiwit P, Sungkanuparph S. Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response. J Med Assoc Thail. 2006;89(12):2028–34.

38.

Chakvetadze C, Bani-Sadr F, Le Pendeven C, et al. Serologic response to hepatitis B vaccination in HIV-infected patients with isolated positivity for antibodies to hepatitis B core antigen. Clin Infect Dis. 2010;50(8):1184–6. https://doi.org/10.1086/651422.CrossRefPubMed

39.

Piroth L, Launay O, Michel ML, et al. Vaccination against hepatitis B virus (HBV) in HIV-1-infected patients with isolated anti-HBV Core antibody: the ANRS HB EP03 CISOVAC prospective study. J Infect Dis. 2016;213(11):1735–42. https://doi.org/10.1093/infdis/jiw011.CrossRefPubMed

40.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. August 2017. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/344/hbv.

41.

Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system. Ann Intern Med. 2017;166(11):792–8. https://doi.org/10.7326/M17-0377.CrossRefPubMed

42.

Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66(1):27–36. https://doi.org/10.1002/hep.29135.CrossRefPubMed

43.

Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66(1):13–26. https://doi.org/10.1002/hep.29109.CrossRefPubMed

44.

Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132–6. https://doi.org/10.1016/j.cgh.2016.06.023.CrossRefPubMed

45.

Sulkowski MS, Chuang WL, Kao JH, et al. No evidence of reactivation of hepatitis B virus among patients treated with Ledipasvir-Sofosbuvir for hepatitis C virus infection. Clin Infect Dis. 2016;63(9):1202–4. https://doi.org/10.1093/cid/ciw507.PubMed

46.

Liu CH, Liu CJ, Su TH, et al. Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection. Open Forum Infect Dis. 2017;4(1):ofx028. https://doi.org/10.1093/ofid/ofx028.CrossRefPubMedPubMedCentral

47.

Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antivir Ther. 2016;21(7):605–9. https://doi.org/10.3851/IMP3066.CrossRefPubMed

48.

Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with Sofosbuvir and Simeprevir. Clin Infect Dis. 2015;61(8):1304–6. https://doi.org/10.1093/cid/civ474.CrossRefPubMed

49.

De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27–30. https://doi.org/10.1016/j.jcv.2016.02.026.CrossRefPubMed

50.

Fabbri G, Mastrorosa I, Vergori A, et al. Reactivation of occult HBV infection in an HIV/HCV co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. BMC Infect Dis. 2017;17(1):182. https://doi.org/10.1186/s12879-017-2287-y.CrossRefPubMedPubMedCentral

51.

Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164. https://doi.org/10.1186/s13256-015-0630-8.CrossRefPubMedPubMedCentral

52.

Hayashi K, Ishigami M, Ishizu Y, et al. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol. 2016;9(4):252–6. https://doi.org/10.1007/s12328-016-0657-4.CrossRefPubMed

53.

Madonia S, Orlando E, Madonia G, Cannizzaro M. HCV/HBV coinfection: the dark side of DAAs treatment? Liver Int. 2017;37(7):1086–7. https://doi.org/10.1111/liv.13342.CrossRefPubMed

54.

Loggi E, Gitto S, Galli S, et al. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. J Clin Virol. 2017;93:66–70. https://doi.org/10.1016/j.jcv.2017.05.021.CrossRefPubMed

55.

Kawagishi N, Suda G, Onozawa M, et al. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J Viral Hepat. 2017;24(12):1098–106. https://doi.org/10.1111/jvh.12737.CrossRefPubMed

56.

Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34(2):404–10. https://doi.org/10.1053/jhep.2001.26511.CrossRefPubMed

57.

Dai CY, Yu ML, Chuang WL, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2001;16(6):636–40.CrossRefPubMed

58.

Zhu W, Wu C, Deng W, et al. Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo. PLoS One. 2012;7(9):e45146. https://doi.org/10.1371/journal.pone.0045146.CrossRefPubMedPubMedCentral

59.

Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol. 2015;28(2):221–8.PubMedPubMedCentral

60.

Yu ML, Lee CM, Chen CL, et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology. 2013;57(6):2135–42. https://doi.org/10.1002/hep.26266.CrossRefPubMed

61.

Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–95. https://doi.org/10.1056/NEJMoa043470.CrossRefPubMed

62.

AASLD/IDSA. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. April 2017. www.hcvguidelines.org.

63.

VA HIV, Hepatitis, and Public Health Pathogens Program. Recommendations for Hepatitis B Viral Infection Testing and Monitoring among HCV-Infected Veterans Being Considered for DAA Treatment. October 2016. https://www.hepatitis.va.gov/pdf/hbv-recommendations-hcv-daa-treatment.pdf.

Titel: Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era
verfasst von: Jennifer J. Chang
Neaka Mohtashemi
Debika Bhattacharya
Publikationsdatum: 23.03.2018
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 2/2018
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-018-0379-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

15.04.2024 | Inkretinmimetika | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Fast jeder zehnte Magen bei Endoskopie noch nicht entleert

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Blutdrucksenkung per Spritze additiv zur Standardtherapie wirksam

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Quarter Century of Anti-HIV CAR T Cells

Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV

Sex Differences in HIV Infection

Genetic Cluster Analysis for HIV Prevention

The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions

Network-Based Research on Rural Opioid Use: an Overview of Methods and Lessons Learned

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Fast jeder zehnte Magen bei Endoskopie noch nicht entleert

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Blutdrucksenkung per Spritze additiv zur Standardtherapie wirksam

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Innere Medizin